The Latest Cardiac and Vascular News
Company’s first female executive to lead commercialization efforts of BIOLIFE4D’s live-saving 3D bioprinting technologies CHICAGO, Sept. 21, 2020 (GLOBE NEWSWIRE) — BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has named Kate Lewis as President of the company. She […]
Birla co-published paper with Stuart K. Williams, a renowned industry figure, to highlight 3D bioprinting’s impact on cardiac failure treatment CHICAGO, Feb. 27, 2020 (GLOBE NEWSWIRE) — BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced its Chief Science Officer, Dr. […]
Pioneering biotech company reaches significant milestone, using proprietary bioink to successfully 3D bioprint a mini-heart with full structure of a whole heart, including chambers and ventricles CHICAGO, Sept. 09, 2019 (GLOBE NEWSWIRE) — BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today […]
CHICAGO, June 25, 2018 (GLOBE NEWSWIRE) — BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has successfully demonstrated its ability to 3D bioprint human cardiac tissue – specifically, a human cardiac patch. The scientific milestone was accomplished within days […]
CHICAGO, Jan. 02, 2018 (GLOBE NEWSWIRE) — BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has named Dr. Ravi Birla as its Chief Science Officer. Birla previously served as the Associate Director of the Department of Stem Cell Engineering […]
CHICAGO, Oct. 13, 2017 /PRNewswire/ — Bioprinting startup BIOLIFE4D named accomplished thoracic and cardiac surgeon Jeffrey Morgan M.D., FACS, FACC as Chief Medical Officer, further bolstering its world-class leadership team. BIOLIFE4D is a pioneering biotech company focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant. Joining […]
CHICAGO, Sept. 7, 2017 /PRNewswire/ — BIOLIFE4D announced it filed a $50 million initial public offering with the Securities and Exchange Commission (SEC) under Regulation A+ rules, allowing everyday investors to help the company bring its groundbreaking cardiac tissue regeneration and organ replacement process to market. Chicago-based BIOLIFE4D is a pioneering biotech company focused on leveraging […]
